



**Patient Group Direction For The Administration Of Hepatitis A
Vaccine For Travel Indications By Approved Healthcare Professionals
Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside
And Western Isles**

Lead Author: Adapted from Public Health Scotland Administration of Hepatitis A Vaccine for Travel Indications Patient Group Direction (PGD) template Version 2.1 – PHS Publication date 6 th January 2025		Approver: NoS PGD Group Authorisation: NHS Grampian
---	--	--

Signature: 		Signature: 
--	--	--

NoS Identifier: NoS/PGD/Travel/HepA/ 1460	Review Date: December 2027 Expiry Date: December 2027	Date Approved by NoS: 29 th January 2025
--	--	---

NHS Grampian, Highland, Orkney, Shetland, Tayside and Western Isles have authorised this Patient Group Direction to help individuals by providing them with more convenient access to an efficient and clearly defined service within the NHS Boards. This Patient Group Direction cannot be used until Appendix 1 and 2 are completed.

Uncontrolled when printed

Version 2.1

Revision History for NoS:

NoS PGD that has been superseded	NoS/PGD/Travel_HepA/1460, Version 2
----------------------------------	-------------------------------------

Most recent changes NoS

Version	Date of change	Summary of Changes	Section heading
2.1	January 2025	Reference to NoS Appendix 1 and 2	Authorisation
		Training requirements for NoS	Continuing education and training

PHS recent changes

Version	Date	Summary of changes
2.1	January 2025	<p>The following changes have been made to V2.0 of this PGD:</p> <ul style="list-style-type: none"> Inclusion criteria section updated in respect of recommendation sources. Audit Section updated to request vaccinators to record the source of recommendation.

Review date: The review date for a PGD needs to be decided on a case-by-case basis in the interest of safety. The expiry date should not be more than 3 years, unless a change in national policy or update is required.

Contents Page

Authorisation	3
1. Clinical Situation	4
2. Description Of Treatment	6
3. Adverse Reactions	10
4. Characteristics Of Staff Authorised Under The PGD	12
5. Audit Trail	13
6. Additional References	14
7. Version History	14
Appendix 1 - Healthcare Professional Agreement to Administer Medicine(s) Under Patient Group Direction	16
Appendix 2 - Healthcare Professionals Authorisation to Administer Medicine(s) Under Patient Group Direction	17

Authorisation




This specimen Patient Group Direction (PGD) template has been produced by Public Health Scotland and adapted by North of Scotland PGD Group (NoS) to assist NHS Boards. NHS Boards should ensure that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may administer vaccine under this PGD can only do so as named individuals. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct and to ensure familiarity with the manufacturer's product information/Summary of Product Characteristics (SmPC) for all vaccines administered in accordance with this PGD.

NHS Board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation. Administration of the vaccine has to be by the same practitioner who has assessed the patient under the PGD.

All authorised staff are required to read the PGD and sign the Agreement to Administer Medicines Under PGD ([Appendix 1](#)).


A Certificate of Authorisation ([Appendix 2](#)) signed by the authorising professional/manager should be supplied. This should be held in the individual health professional's records, or as agreed within the individual Health Board.

This PGD has been produced for NoS by:					
Doctor	Daniel Chandler	Signature		Date Signed	25/03/2024
Pharmacist	Gayle MacDonald	Signature		Date Signed	05/04/2024
Nurse	Pauline Merchant	Signature		Date Signed	27/03/2024

Approved for use within NoS by:

NoS Group Chair	Signature	Date Signed
Lesley Coyle		20/01/2025

Authorised and executively signed for use within NoS by:

NHS Grampian Chief Executive	Signature	Date Signed
Adam Coldwells – Interim Chief Executive		29/01/2025

Version 2.1 – Approved for NoS from 29th January 2025

1. Clinical Situation

1.1. Indication

Active immunisation of individuals who are deemed to be at risk from exposure to hepatitis A virus.

1.2. Inclusion criteria

Adults and children aged 1 year and over who:

- Intend to travel to or reside in countries where hepatitis A vaccination is currently recommended by recognised Scottish or UK national travel health websites to ensure adherence to the latest recommendations.

The risk of exposure should be determined after careful risk assessment of an individual's itinerary, duration of stay, planned activities and medical history.

Valid consent has been given to receive the vaccine.

1.3. Exclusion criteria

Individuals who:

- are under one year of age
- have had a confirmed anaphylactic reaction to a previous dose of any hepatitis A containing vaccine or to any components of the vaccine, these may include neomycin and/or formaldehyde (refer to relevant SmPC)
- have a history of severe (i.e. anaphylactic reaction) to latex where the vaccine is not latex free
- are solely at occupational risk of hepatitis A exposure, should be referred to their employer's occupational health provider for vaccination
- previous confirmed hepatitis A infection
- suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation).

1.4. Cautions/need for further advice/ circumstances when further advice should be sought from a doctor

The Green Book advises there are very few individuals who cannot receive hepatitis A containing vaccines.

When there is doubt, appropriate advice should be sought from the immunisation co-ordinator or health protection team rather than withholding the vaccine.

Individuals with immunosuppression and HIV infection can be given hepatitis A containing vaccines although seroconversion rates and antibody titre may be lower. Specialist advice may be required.

Avaxim® vaccines contain 10microgram phenylalanine in each 0.5mL dose, which is equivalent to 0.17microgram/kg for a 60kg person. Phenylalanine may be harmful for individuals with phenylketonuria (PKU). The amount in the vaccine is unlikely to adversely affect individuals with PKU, but they should be advised Avaxim® vaccines contain 10micrograms of phenylalanine. These individuals will be well versed as to the amounts they can tolerate in their diet. If available offer an alternative vaccine. Havrix® Monodose also has trace amino acids, so VAQTA® would be the preferred option. Alternatively, seek advice from the specialist endocrinologist/metabolic physician looking after the individual with PKU to confirm they are content for them to have Avaxim®.

The presence of a neurological condition is not a contraindication to immunisation but if there is evidence of current neurological deterioration, deferral of vaccination may be considered, to avoid incorrect attribution of any change in the underlying condition. The risk of such deferral should be balanced against the risk of the preventable infection and vaccination should be promptly given once the diagnosis and/or the expected course of the condition becomes clear.

Co-administration of other vaccines

Hepatitis A-containing vaccines can be given at the same time as other vaccines such as hepatitis B, MMR, MenACWY, Td/IPV and other travel vaccines. When administering at the same time as other vaccines, care should be taken to ensure that the appropriate route of injection is used for all the vaccinations. The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each was given should be noted in the individual's records.

Syncope

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Pregnancy and breastfeeding

There is no evidence of risk from vaccinating pregnant women, or those who are breast-feeding, with inactivated virus or bacterial vaccines or toxoids. Vaccination should be considered when the risk of infection is high and benefits are considered to outweigh the risks.

1.5. Action if excluded

Specialist advice must be sought on the vaccine and circumstances under which it could be given. Immunisation using a patient specific direction may be indicated. The risk to the individual of not being immunised must be taken into account.

Document the reason for exclusion and any action taken in accordance with local procedures.

Inform or refer to the clinician in charge.

Advise the individual/parent/carer of preventative measures to reduce exposure to hepatitis A including careful attention to food and water hygiene, scrupulous hand hygiene and maintenance of high standards of personal hygiene during sex, as appropriate.

Temporary exclusion

In case of postponement due to acute severe febrile illness, arrange a future date for immunisation.

1.6. Action if patient declines

Advise the individual about the protective effects of the vaccine, the risks of infection and potential complications of disease.

Advise the individual/parent/carer of preventative measures to reduce exposure to hepatitis A including careful attention to food and water hygiene and scrupulous hand hygiene and maintenance of high standards of personal hygiene during sex, as appropriate.

Advise how future immunisation may be accessed if they subsequently decide to receive the vaccine.

Document advice given and decision reached.

Inform or refer to the clinician in charge.

2. Description Of Treatment

2.1. Name of medicine/form/strength

Hepatitis A (inactivated) vaccine (adsorbed), either:

Havrix® Monodose vaccine, hepatitis A virus 1440 ELISA units in a pre-filled syringe or vial.

Havrix® Junior Monodose vaccine, hepatitis A virus 720 ELISA units in a pre-filled syringe or vial.

AVAXIM®, hepatitis A virus, (GBM strain) 160U, suspension for injection in a pre-filled syringe.

AVAXIM® Junior, hepatitis A virus, (GBM strain) 80U, suspension for injection in a pre-filled syringe.

VAQTA® Adult, hepatitis A virus (strain CR 326F) 50U suspension for injection in a pre-filled syringe or vial.

VAQTA® Paediatric, hepatitis A virus (strain CR 326F) 25U suspension for injection in a pre-filled syringe or vial.

2.2. Route of administration

Vaccines are routinely given intramuscularly into the upper arm or anterolateral thigh.

Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with the individual's bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. If the individual receives medication/treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication/ treatment is administered. Individuals on stable anticoagulation therapy, including individuals on warfarin who are up to date with their scheduled INR testing and whose latest INR was below the upper threshold of their therapeutic range, can receive intramuscular vaccination. A fine needle (equal to 23 gauge or finer calibre such as 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. If in any doubt, consult with the clinician responsible for prescribing or monitoring the individual's anticoagulant therapy.

The vaccine must be reconstituted in accordance with the manufacturer's instructions prior to administration.

The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

2.3. Dosage

Current UK licensed hepatitis A vaccines contain different concentrations of antigen per millilitre (see table below). The choice of vaccine and dose used should be guided by the individual's age, immunocompetence and dose recommendations in the vaccine manufacturer's SmPC.

Vaccine product	Ages	Dose	Volume
Havrix® Monodose	16 years or over	1440 units	1.0mL
Havrix® Junior Monodose	One to 15 years	720 units	0.5mL
Avaxim®	16 years or over	160 units	0.5mL
Avaxim® Junior	One to 15 years	80 units	0.5mL
Vaqta® Adult	18 years or over	50 units	1.0mL
Vaqta® Paediatric	One to 17 years	25 units	0.5mL

2.4. Frequency

Primary immunisation

Single dose (see table above).

Vaccination should ideally occur at least 2 weeks prior to possible exposure to infection with hepatitis A.

For travellers, vaccine should preferably be given at least two weeks before departure but can be given up to the day of departure.

Reinforcing Immunisation

For those who require prolonged or subsequent protection against infection caused by hepatitis A virus, a single reinforcing booster dose of a hepatitis A-containing vaccine should ideally be given 6 to 12 months after the first dose.

If the booster dose is delayed beyond 12 months, the course does **not** need to be restarted as studies have shown boosting can occur even when the second dose is delayed for several years.

Monovalent hepatitis A containing vaccines may be used interchangeably, as appropriate, to complete a course.

Until further evidence is available on persistence of protective immunity, a further booster at 25 years after reinforcing dose is indicated for those at ongoing risk.

2.5. Duration of treatment

See frequency section.

2.6. Maximum or minimum treatment period

See frequency section.

2.7. Quantity to supply/administer

See frequency section.

2.8. ▼ black triangle medicines

No

2.9. Legal category

Prescription only medicine (POM).

2.10. Is the use outwith the SmPC?

Vaccine should be stored according to the conditions detailed below.

However, in the event of an inadvertent or unavoidable deviation of these conditions refer to NHS Board guidance on storage and handling of vaccines or national vaccine incident guidance.

Where vaccine is assessed in accordance with these guidelines as appropriate for continued use, administration under this PGD is allowed.

2.11. Storage requirements

Vaccine should be stored at a temperature of +2° to +8°C.

Store in the original packaging to protect from light.

Do not freeze.

NHS Board guidance on Storage and Handling of vaccines should be observed.

In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal.

2.12. Additional information

Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered.

Immunological response may be diminished in those receiving immunosuppressive treatment.

3. Adverse Reactions

3.1. Warnings including possible adverse reactions and management of these

For full details/information on possible side effects, refer to the marketing authorisation holder's SmPC.

Adverse reactions to hepatitis A vaccines are usually mild and confined to the first few days after immunisation. The most common reactions are mild, transient soreness, erythema and induration at the injection site. A small, painless nodule may form at the injection site; this usually disappears and is of no consequence.

General symptoms such as fever, malaise, fatigue, headache, nausea and loss of appetite are also reported less frequently. Other commonly reported reactions to hepatitis A vaccination include general symptoms such as fever, malaise, fatigue, irritability, drowsiness, headache, myalgia, arthralgia and gastrointestinal symptoms including nausea, vomiting, diarrhoea, abdominal pain and loss of appetite.

As with all vaccines there is a very small possibility of anaphylaxis and facilities for its management must be available.

In the event of severe adverse reaction individual should be advised to seek medical advice.

3.2. Reporting procedure for adverse reactions

Healthcare professionals and individuals/carers should report all suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on <http://www.mhra.gov.uk/yellowcard>

Any adverse reaction to a vaccine should be documented in accordance with locally agreed procedures in the individual's record and the individual's GP should be informed.

3.3. Advice to patient or carer including written information

Written information to be given to individuals:

- Provide manufacturer's consumer information leaflet/patient information leaflet (PIL) provided with the vaccine.
- Supply immunisation promotional material as appropriate.

Individual advice/follow up treatment:

- Inform the individual/carer of possible side effects and their management.
- Explain that to give long-lasting immunity to hepatitis A, dosing requires two injections at least six months apart.
- Advise the individual/parent/carer of preventative measures to reduce exposure to hepatitis A including careful attention to food and water hygiene, scrupulous hand hygiene and maintenance of high standards of personal hygiene during sex, as appropriate.
- The individual/carer should be advised that hepatitis A vaccine will not prevent infection caused by other pathogens known to infect the liver such as hepatitis B, C and hepatitis E viruses.
- The individual should be advised to seek medical advice in the event of a severe adverse reaction.
- Inform the individual that they can report suspected adverse reactions to the MHRA using the Yellow Card reporting scheme.

3.4. Observation following vaccination

Following immunisation, patients remain under observation in line with NHS Board policy.

As syncope (fainting) can occur following vaccination, all vaccinees should either be driven by someone else or should not drive for 15 minutes after vaccination.

3.5. Follow up

As above.

3.6. Additional facilities

A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever vaccines are given. Immediate treatment should include early treatment with intramuscular adrenaline, with an early call for help and further IM adrenaline every 5 minutes.

The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis.

4. Characteristics Of Staff Authorised Under The PGD

4.1. Professional qualifications

The following classes of registered healthcare practitioners are permitted to administer this vaccine:

- nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)
- pharmacists currently registered with the General Pharmaceutical Council (GPhC)
- pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC)
- chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC)
- dental hygienists and dental therapists registered with the General Dental Council
- optometrists registered with the General Optical Council.

4.2. Specialist competencies or qualifications

Persons must only work under this PGD where they are competent to do so.

All persons operating this PGD:

- demonstrate appropriate knowledge and skills to work under this PGD.
- must be authorised by name by their employer as an approved person under the current terms of this PGD before working to it.
- must be familiar with the vaccine product and alert to changes in the manufacturer's product information/SmPC.
- must be competent to undertake immunisation and to discuss issues related to immunisation to assess patients for vaccination and obtain consent.
- must be competent in the correct storage of vaccines and management of the cold chain if receiving, responsible for, or handling the vaccine.
- must be competent in the recognition and management of anaphylaxis or under the supervision of persons able to respond appropriately to immediate adverse reactions.
- must have access to the PGD and associated online resources.
- should fulfil any additional requirements defined by local policy.

Employer

The employer is responsible for ensuring that persons have the required knowledge and skills to safely deliver the activity they are employed to provide under this PGD.

As a minimum, competence requirements stipulated in the PGD must be adhered to.

4.3. Continuing education and training

All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under this PGD.

- Have undertaken NoS PGD module training on [TURAS](#) Learn
- Have attended basic life support training either face to face or online and updated in-line with individual Board requirements
- Have undertaken immunisation training where available
- Have undertaken NHS e-anaphylaxis training or equivalent which covers all aspects of the identification and management of anaphylaxis updated in-line with individual Board requirements
- Maintain their skills, knowledge and their own professional level of competence in this area according to their individual Code of Professional Conduct.

5. Audit Trail

Record the following information:

- valid informed consent was given
- name of individual, address, date of birth and GP with whom the individual is registered if possible
- name of person that undertook assessment of individual's clinical suitability and subsequently administered the vaccine
- details of the source of the recommendation to vaccinate
- name and brand of vaccine
- date of administration
- dose, form and route of administration of vaccine
- batch number
- where possible expiry date
- anatomical site of vaccination
- advice given, including advice given if excluded or declines immunisation
- details of any adverse drug reactions and actions taken
- administered under PGD.

Records should be kept in line with local procedures.

Local policy should be followed to encourage information sharing with the individual's General Practice

All records should be clear, legible and contemporaneous and in an easily retrievable format.

6. Additional References

Practitioners operating the PGD must be familiar with:

- [Immunisation against Infectious Disease \[Green Book\]](#)
- [Immunisation against infectious disease - Chapter 17 - Hepatitis A](#)
- [Current edition of British National Formulary](#)
- [Marketing authorisation holders Summary of Product Characteristics.](#)
- [Professional Guidance on the Administration of Medicines in Healthcare settings 2019.](#)
- [Professional Guidance on the Safe and Secure Handling of Medicines](#)

7. Version History

Version	Date	Summary of changes
1.0	February 2022	Version 1.0 new PGD
2.0	February 2024	<ul style="list-style-type: none"> • This PGD has undergone minor rewording, layout, formatting changes for clarity and consistency with other PHS national specimen PGDs. • Cautions section updated to include advice for PKU patients and Avaxim[®] preparations • Name of medicine and dosage sections updated to include Avaxim[®] Junior preparation • Additional Information section updated to include additional information on co-administration of other vaccines • Administration section updated to reflect Green Book Chapter wording • Observation following vaccination section updated to include advice on driving post-immunisation. • Off-label section updated to reflect changes to administration section
2.1	January 2025	<p>The following changes have been made to V2.0 of this PGD:</p> <ul style="list-style-type: none"> • Inclusion criteria section updated in respect of recommendation sources • Audit Section updated to request vaccinators to record the source of recommendation.

Version history NoS

Version	Date of change	Summary of Changes	Section heading
2.0	March 2024	Reference to NoS Appendix 1 and 2	Authorisation
		Training requirements for NoS	Continuing education and training
2.1	January 2025	Reference to NoS Appendix 1 and 2	Authorisation
		Training requirements for NoS	Continuing education and training



Appendix 1 - Healthcare Professional Agreement to Administer Medicine(s) Under Patient Group Direction

I: _____ (Insert name)

Working within: _____ e.g. Area, Practice

Agree to administer the medicine(s) contained within the following Patient Group
Direction:

Patient Group Direction For The Administration Of Hepatitis A Vaccine For Travel Indications By Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside And Western Isles, Version 2.1

I have completed the appropriate training to my professional standards enabling me to
administer the medicine(s) under the above direction. I agree not to act beyond my
professional competence, nor out with the recommendations of the direction.

Signed: _____

Print Name: _____

Date: _____

Profession: _____

**Professional Registration
number/PIN:** _____



Appendix 2 - Healthcare Professionals Authorisation to Administer Medicine(s) Under Patient Group Direction

The Lead manager/Professional of each clinical area is responsible for maintaining records of all clinical areas where this PGD is in use, and to whom it has been disseminated.

The Senior Nurse/Professional who approves a healthcare professional to administer the medicine(s) under this PGD is responsible for ensuring that they are competent, qualified and trained to do so, and for maintaining an up-to-date record of such approved persons.

The Healthcare Professional that is approved to administer the medicine(s) under this PGD is responsible for ensuring that they understand and are qualified, trained and competent to undertake the duties required. The approved person is also responsible for ensuring that administration is carried out within the terms of the direction, and according to their individual code of professional practice and conduct.

Patient Group Direction For The Administration Of Hepatitis A Vaccine For Travel Indications By Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside And Western Isles, Version 2.1

Local clinical area(s) where the listed healthcare professionals will operate under this PGD:

Name of Healthcare Professional	Signature	Date	Name of Manager	Signature	Date

**Patient Group Direction For The Administration Of Hepatitis A Vaccine
For Travel Indications By Approved Healthcare Professionals Working
Within NHS Grampian, Highland, Orkney, Shetland, Tayside And Western
Isles, Version 2.1**

Name of Healthcare Professional	Signature	Date	Name of Manager	Signature	Date